Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms VACIMRA
- 31 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 09 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2019.
- 09 May 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2018.